A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients.
Authors
Joseph, NuradhTaylor, Cathy M
O'Hara, Catherine
Choudhury, Ananya
Elliott, Tony
Logue, John P
Wylie, James P
Affiliation
10.1016/j.radonc.2016.09.016Issue Date
2016-10-28
Metadata
Show full item recordAbstract
Dose escalation has been shown to improve biochemical outcome in localised prostate cancer. An HDR brachytherapy boost is an effective strategy for dose escalation, since it exploits the low α/β ratio in prostate cancer, allowing the delivery of a high biological dose to the tumour. We sought to evaluate the biochemical disease free survival in patients with intermediate and high risk localised prostate cancer treated with EBRT plus HDR brachytherapy as a boost, in our institution.Citation
A combined single high-dose rate brachytherapy boost with hypofractionated external beam radiotherapy results in a high rate of biochemical disease free survival in localised intermediate and high risk prostate cancer patients. 2016, Radiother OncolJournal
Radiotherapy and OnologyDOI
10.1016/j.radonc.2016.09.016PubMed ID
28029404Type
ArticleLanguage
enISSN
1879-0887ae974a485f413a2113503eed53cd6c53
10.1016/j.radonc.2016.09.016
Scopus Count
Collections
Related articles
- Long-term outcome by risk factors using conformal high-dose-rate brachytherapy (HDR-BT) boost with or without neoadjuvant androgen suppression for localized prostate cancer.
- Authors: Galalae RM, Martinez A, Mate T, Mitchell C, Edmundson G, Nuernberg N, Eulau S, Gustafson G, Gribble M, Kovács G
- Issue date: 2004 Mar 15
- Long term results of a prospective dose escalation phase-II trial: interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer.
- Authors: Lettmaier S, Lotter M, Kreppner S, Strnad A, Fietkau R, Strnad V
- Issue date: 2012 Aug
- Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial.
- Authors: Martinez AA, Kestin LL, Stromberg JS, Gonzalez JA, Wallace M, Gustafson GS, Edmundson GK, Spencer W, Vicini FA
- Issue date: 2000 May 1
- Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
- Authors: Martinez AA, Demanes DJ, Galalae R, Vargas C, Bertermann H, Rodriguez R, Gustafson G, Altieri G, Gonzalez J
- Issue date: 2005 Aug 1
- Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation.
- Authors: Vicini FA, Kestin LL, Martinez AA
- Issue date: 2000 Jun